ICON Acquires Mapi Group

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has acquired the Mapi Group, a patient-centered health outcomes research and commercialization company.
 
The acquisition strengthens ICON’s existing Commercialisation and Outcomes Research business, adding significant commercialization presence, analytics, real-world evidence generation, and strategic regulatory expertise. The combined organization will be a leader for real world evidence, post approval research, language services, consultancy services supporting clinical outcomes assessments, pricing and market access, and scientific communications.
 
The acquisition also enables ICON to have direct access to Mapi Research Trust, the industry’s most subscribed library of clinical outcomes assessments (COAs), with exclusive distribution of more than 300 families of validated questionnaires, including licensing of COA services used by commercial, academic and regulatory research organizations.
 
“The late phase CRO market continues to grow as our customers face greater scrutiny from regulators and reimbursement bodies around real-world evidence of product value and safety,” commented Dr. Steve Cutler, CEO of ICON. “The acquisition of Mapi extends the breadth and depth of ICON’s late phase capabilities, creating an industry-leading provider of post-approval research, spanning evidence generation, strategic regulatory services, scientific communications and commercial strategy. Our customers will also benefit from ICON’s access to the industry’s broadest set of COA tools and instruments as well as new and enhanced real world data sets. Mapi has been a pioneer of late phase and outcomes research since their foundation and we are delighted to welcome their team of experts to ICON.”
 
“By combining with ICON, our customers will have access to a broader global footprint, additional depth of experience, new scientific communication services and access to innovative solutions to capture real world data from patients,” said James Karis, CEO of Mapi Group. “In addition, our customers will have access to a wide range of global clinical services, spanning all phases of development. Mapi and ICON are an ideal combination, having complimentary services and a shared mission to provide superior research solutions that help improve the lives of patients globally.”
 
“I am delighted that Mapi will become part of ICON, a company that has a similar culture and vision that will enable Mapi to continue the focus on innovation that we have developed over the last forty-three years,” said Bernard Jambon, Mapi’s founder and board chairman.
 
Mapi Group has more than 40 years of experience supporting life-science companies as a patient-centered research company in commercializing novel treatments through real-world evidence, strategic regulatory services, pharmacovigilance, market access, and language services. Mapi Group is a provider of health research and commercialization services to life-science companies enabling market authorization, market access and market adoption of novel therapeutics.
 
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in the strategic development, management, and analysis of programs that support clinical development,from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 84 locations in 38 countries and has approximately 12,300 employees.